Abstract: Immune checkpoint inhibitors (ICI) have shown efficacy for some patients with gynecological tumors, which are mainly used to treat persistent, recurrent, or metastatic patients. Immunotherapy with ICI has shown good objective responses and survival benefit in patients with endometrial cancer. However, the rate of response to immunotherapy in patients with ovarian cancer remains modest. Some patients with recurrent or resistant gestational trophoblastic neoplasia benefit from ICI. ICI often has optimal duration of response. Accurately evaluating the indications and responses, recognizing and managing immune-related adverse events are essential to ICI treatment. With regards to ICI, the clinical benefit of monotherapy is limited; however, combinations of ICI with other therapies may have clinical benefit.